Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.40 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5169770 | 0.86 | ALDH1A1 (0.46) | MEN1KMT2AATMPTPN1MAPT | |
| SCHEMBL4888122 | 0.84 | GABRA2 (0.61) | KMT2AGABRA2GABRB2 | |
| SCHEMBL14022800 | 0.84 | GPBAR1 (0.42) | MEN1KMT2AMAPTSMN1; SMN2TP53 | |
| SCHEMBL14022801 | 0.83 | MEN1 (0.42) | MEN1KMT2AATMPTPN1MAPT | |
| SCHEMBL5169774 | 0.81 | KMT2A (0.45) | MEN1KMT2AATMPTPN1GABRA2 | |
| SCHEMBL27739164 | 0.78 | GABRA2 (0.51) | SMN1; SMN2GABRA2GABRB2TBXA2RPTGER1 | |
| SCHEMBL4894803 | 0.77 | POLB (0.40) | MEN1KMT2AMAPTSMN1; SMN2TP53 | |
| SCHEMBL2683055 | 0.76 | HTR2A (0.50) | SMN1; SMN2GABRA2GABRB2 | |
| SCHEMBL1079580 | 0.75 | HTR2A (0.49) | SMN1; SMN2GABRA2GABRB2 | |
| SCHEMBL14022802 | 0.75 | MAPT (0.43) | MEN1KMT2AMAPTSMN1; SMN2GABRA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080242716-A1 | calcium channel modulator; [1-(4-Chloro-phenyl)-2-(4-fluoro-benzyl)-1H-imidazol-4-ylmethyl]-(4-fluoro-phenyl)-)-methyl-amine; analgesic, antidiabetic agent; angina, hypertension, myocardial ischemia, arrhythmia, diabetes, urinary incontinence, stroke, pain, brain injury, or neuronal disorders | SCION PHARMACEUTICALS, INC. | 2008-10-02 | — | — | US | disclosed |
| US-20080242716-A1 | calcium channel modulator; [1-(4-Chloro-phenyl)-2-(4-fluoro-benzyl)-1H-imidazol-4-ylmethyl]-(4-fluoro-phenyl)-)-methyl-amine; analgesic, antidiabetic agent; angina, hypertension, myocardial ischemia, arrhythmia, diabetes, urinary incontinence, stroke, pain, brain injury, or neuronal disorders | SCION PHARMACEUTICALS, INC. | 2008-10-02 | — | — | US | disclosed |
| US-20080242716-A1 | calcium channel modulator; [1-(4-Chloro-phenyl)-2-(4-fluoro-benzyl)-1H-imidazol-4-ylmethyl]-(4-fluoro-phenyl)-)-methyl-amine; analgesic, antidiabetic agent; angina, hypertension, myocardial ischemia, arrhythmia, diabetes, urinary incontinence, stroke, pain, brain injury, or neuronal disorders | SCION PHARMACEUTICALS, INC. | 2008-10-02 | — | — | US | disclosed |
| US-20070281937-A1 | Ion Channel Modulators | SCION PHARMACEUTICALS, INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070281937-A1 | Ion Channel Modulators | SCION PHARMACEUTICALS, INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070281937-A1 | Ion Channel Modulators | SCION PHARMACEUTICALS, INC. | 2007-12-06 | — | — | US | disclosed |
| EP-1722787-A4 | ION CHANNEL MODULATORS | WYETH CORP (US) | 2007-09-26 | — | — | EP | disclosed |
| CN-1938022-A | Ion channel modulators | SCION PHARMACEUTICALS INC (US) | 2007-03-28 | — | — | CN | disclosed |
| CN-1930132-A | Ion channel modulators | WYETH CORP (US) | 2007-03-14 | — | — | CN | disclosed |
| EP-1722787-A1 | ION CHANNEL MODULATORS | Wyeth a Corporation of the State of Delaware (US) | 2006-11-22 | — | — | EP | disclosed |
| EP-1723117-A2 | ION CHANNEL MODULATORS | Wyeth a Corporation of the State of Delaware (US) | 2006-11-22 | — | — | EP | disclosed |
| WO-2005087229-A1 | ION CHANNEL MODULATORS | WYETH (US) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005086836-A2 | ION CHANNEL MODULATORS | WYETH (US) | 2005-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281937-A1 | Ion Channel Modulators | CACNA1B, CACNA1C, TRPV1 | MEN1 3147/4885KMT2A 3236/4885ATM 4312/4885 |
| US-20080242716-A1 | calcium channel modulator; [1-(4-Chloro-phenyl)-2-(4-fluoro-benzyl)-1H-imidazol-4-ylmethyl]-(4-fluoro-phenyl)-)-methyl-amine; analgesic, antidiabetic agent; angina, hypertension, myocardial ischemia, arrhythmia, diabetes, urinary incontinence, stroke, pain, brain injury, or neuronal disorders | CACNA1D, CACNA1C, TRPV1 | MEN1 3786/4885KMT2A 836/4885ATM 2826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.